Arterial EMBOLism After Catheter Ablation of Atrial Fibrillation (EMBOL AF)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The EMBOL-AF is a multicenter, international, observational study designed as a retrospective registry that will investigate the characteristics of systemic arterial embolic events after treatment of atrial fibrillation by catheter ablation. Due to the retrospective nature of the study, the registry is specially focused on cerebral embolism (stroke and TIA) because these are not only the most frequent and clinically relevant but also the most susceptible to underreporting. However, all embolism associated to AFAbl will be included. This study will gather all clinically relevant aspects and data of all cases of arterial embolism that have occurred over the last 5 years in the centers that will participate in the registry. Based on these reported cases, the incidence, management and outcomes of embolic events (particularly stroke and TIA) will be studied.

Eligibility
Participation Requirements
Sex: All
View:

• Systemic arterial embolism (stroke, TIA or any other symptomatic event) after catheter ablation for AF or left atrial macroreentrant atrial tachycardia or left atrial flutter that have occurred between 1st january 2017 and 31st july 2023.

• The embolic event must be associated with the ablation procedure, therefore, it must have occurred during the procedure or during the first 7 days after it, during hospital stay or after discharge.

Locations
Other Locations
Spain
Departmen of Cardiology, La Paz University Hospital
RECRUITING
Madrid
Contact Information
Primary
Sergio Castrejón Cstrejón, MD PhD
castrejonxp@gmail.com
+34 941 207 13 01
Backup
Beatriz Sanz Verdejo, Engineer
embolaf.registry@gmail.com
+34 941 207 13 01
Time Frame
Start Date: 2024-01-02
Estimated Completion Date: 2024-12-01
Participants
Target number of participants: 500
Treatments
Patients with embolism after ablation for atrial fibrillation (or left atrial flutter).
The EMBOL-AF is a multicenter, international, observational study designed as a retrospective registry that will investigate the characteristics of systemic arterial embolic events after treatment of atrial fibrillation by catheter ablation. Due to the retrospective nature of the study, the registry is specially focused on cerebral embolism (stroke and TIA) because these are not only the most frequent and clinically relevant but also the most susceptible to underreporting. However, all embolism associated to AFAbl will be included.~This study will gather all clinically relevant aspects and data of all cases of arterial embolism that have occurred over the last 5 years in the centers that will participate in the registry. Based on these reported cases, the incidence, management and outcomes of embolic events (particularly stroke and TIA) will be studied.
Sponsors
Collaborators: Department of Rhythmology, University Hospital Schleswig-Holstein, Lübeck, Germany., 3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.
Leads: Hospital Universitario La Paz

This content was sourced from clinicaltrials.gov